BIOATLA, INC. Research and Development Expense
BIOATLA, INC. (BCAB) reported Research and Development Expense of $3.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- BIOATLA, INC. research and development expense for the quarter ending 2026-06-30 was $3.34M, a 75.58% decline year-over-year.
- BIOATLA, INC. research and development expense for the quarter ending 2026-03-31 was $4.58M, a 62.91% decline year-over-year.
- BIOATLA, INC. research and development expense for the quarter ending 2025-12-31 was $8.00M, a 31.37% decline year-over-year.
- BIOATLA, INC. research and development expense for the quarter ending 2025-09-30 was $9.54M, a 41.82% decline year-over-year.
- BIOATLA, INC. research and development expense for fiscal 2025 was $43.57M, a 30.94% decline from fiscal 2024.
- BIOATLA, INC. research and development expense for fiscal 2024 was $63.09M, a 39.17% decline from fiscal 2023.
- BIOATLA, INC. research and development expense for fiscal 2023 was $103.73M, a 30.73% increase from fiscal 2022.
- BIOATLA, INC. research and development expense for fiscal 2022 was $79.35M, a 36.16% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.34M 10-Q · filed 2026-08-13 | $7.92M 10-Q · filed 2026-08-13 | $15.92M derived: sum of 3 quarters · filed 2026-08-13 | $25.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.58M 10-Q · filed 2026-05-15 | $12.58M derived: sum of 2 quarters · filed 2026-05-15 | $22.12M derived: sum of 3 quarters · filed 2026-05-15 | $35.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $17.53M derived: sum of 2 quarters · filed 2026-03-31 | $31.22M derived: sum of 3 quarters · filed 2026-08-13 | $43.57M 10-K · filed 2026-03-31 |
| 2025-09-30 | $9.54M 10-Q · filed 2025-11-13 | $23.22M derived: sum of 2 quarters · filed 2026-08-13 | $35.58M 10-Q · filed 2025-11-13 | $47.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $13.68M 10-Q · filed 2026-08-13 | $26.04M 10-Q · filed 2026-08-13 | $37.69M derived: sum of 3 quarters · filed 2026-08-13 | $54.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $12.36M 10-Q · filed 2026-05-15 | $24.00M derived: sum of 2 quarters · filed 2026-05-15 | $40.40M derived: sum of 3 quarters · filed 2026-05-15 | $56.60M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $28.05M derived: sum of 2 quarters · filed 2026-03-31 | $44.24M derived: sum of 3 quarters · filed 2026-03-31 | $63.09M 10-K · filed 2026-03-31 |
| 2024-09-30 | $16.39M 10-Q · filed 2025-11-13 | $32.59M derived: sum of 2 quarters · filed 2025-11-13 | $51.45M 10-Q · filed 2025-11-13 | $74.12M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $16.20M 10-Q · filed 2025-08-07 | $35.05M 10-Q · filed 2025-08-07 | $57.72M derived: sum of 3 quarters · filed 2025-08-07 | $86.12M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $18.85M 10-Q · filed 2025-05-06 | $41.53M derived: sum of 2 quarters · filed 2025-05-06 | $69.93M derived: sum of 3 quarters · filed 2025-05-06 | $100.89M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $22.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $51.07M derived: sum of 2 quarters · filed 2025-03-28 | $82.03M derived: sum of 3 quarters · filed 2025-03-28 | $103.73M 10-K · filed 2025-03-28 |
| 2023-09-30 | $28.40M 10-Q · filed 2024-11-07 | $59.36M derived: sum of 2 quarters · filed 2024-11-07 | $81.06M 10-Q · filed 2024-11-07 | $102.93M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $30.96M 10-Q · filed 2024-08-08 | $52.66M 10-Q · filed 2024-08-08 | $74.53M derived: sum of 3 quarters · filed 2024-08-08 | $94.37M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $21.70M 10-Q · filed 2024-05-14 | $43.57M derived: sum of 2 quarters · filed 2024-05-14 | $63.41M derived: sum of 3 quarters · filed 2024-05-14 | $84.12M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $21.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $41.71M derived: sum of 2 quarters · filed 2024-03-26 | $62.42M derived: sum of 3 quarters · filed 2024-03-26 | $79.35M 10-K · filed 2024-03-26 |
| 2022-09-30 | $19.84M 10-Q · filed 2023-11-07 | $40.55M derived: sum of 2 quarters · filed 2023-11-07 | $57.47M 10-Q · filed 2023-11-07 | $73.92M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $20.71M 10-Q · filed 2023-08-01 | $37.63M 10-Q · filed 2023-08-01 | $54.08M derived: sum of 3 quarters · filed 2023-08-01 | $70.64M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | $16.92M 10-Q · filed 2023-05-11 | $33.37M derived: sum of 2 quarters · filed 2023-05-11 | $49.92M derived: sum of 3 quarters · filed 2023-05-11 | $64.77M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $16.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $33.00M derived: sum of 2 quarters · filed 2023-03-23 | $47.85M derived: sum of 3 quarters · filed 2023-03-23 | $58.27M 10-K · filed 2023-03-23 |
| 2021-09-30 | $16.55M 10-Q · filed 2022-11-04 | $31.40M derived: sum of 2 quarters · filed 2022-11-04 | $41.83M 10-Q · filed 2022-11-04 | $52.31M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $14.85M 10-Q · filed 2022-08-09 | $25.27M 10-Q · filed 2022-08-09 | $35.76M derived: sum of 3 quarters · filed 2022-08-09 | $40.62M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $10.42M 10-Q · filed 2022-05-05 | $20.91M derived: sum of 2 quarters · filed 2022-05-05 | $25.77M derived: sum of 3 quarters · filed 2022-05-05 | $28.70M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $15.35M derived: sum of 2 quarters · filed 2022-02-28 | $18.27M derived: sum of 3 quarters · filed 2022-02-28 | $19.93M 10-K · filed 2022-02-28 |
| 2020-09-30 | $4.86M 10-Q · filed 2021-11-15 | $7.79M derived: sum of 2 quarters · filed 2021-11-15 | $9.45M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.92M 10-Q · filed 2021-08-13 | $4.58M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.66M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $25.92M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |